Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the two alternatives as equivalent therapeutic alternatives.PMID:37612185 | DOI:10.1016/j.farma.2023.07.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
B-cell prolymphocytic leukemia with P53 abnormalities successfully treated with bendamustine and rituximab: a report of three cases
CONCLUSIONS: This case series suggests that BR regimen is promising for bringing deep remission to patients with B-PLL. Prospective trials are still required for further elucidation.PMID:37588745 | PMC:PMC10425637 | DOI:10.21037/tcr-23-828 (Source: Cell Research)
Source: Cell Research - August 17, 2023 Category: Cytology Authors: Anna Wang Wei Guo Daniela Damiani Vikram Sumbly Gaurav Goyal Zhonghua Du Ou Bai Source Type: research
Cancers, Vol. 15, Pages 4047: Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study
This study expands the information available on patients with CLL in Spain, describing the diversity in patient characteristics and therapeutic approaches in clinical practice. (Source: Cancers)
Source: Cancers - August 10, 2023 Category: Cancer & Oncology Authors: Javier Loscertales Pau Abrisqueta-Costa Antonio Gutierrez Jos é Ángel Hernández-Rivas Rafael Andreu-Lapiedra Alba Mora Carolina Leiva-Farr é Mar ía Dolores López-Roda Ángel Callejo-Mellén Esther Álvarez-García Jos é Antonio García-Marco Tags: Article Source Type: research
Successful treatment of relapsed/refractory transformed aggressive B-cell lymphoma with polatuzumab vedotin combined with bendamustine and rituximab followed by non-myeloablative related HLA-haploidentical stem cell transplantation
(Source: Annals of Hematology)
Source: Annals of Hematology - August 10, 2023 Category: Hematology Source Type: research
A Real-World Disproportionality Analysis of Drug-Induced Immune Hemolytic Anemia in the FDA Adverse Event Reporting System
CONCLUSIONS: Our study identified the most common drugs that could induce DIIHA in adults and children, as well as the respective ROR and PRR value to discover new drug signals. This study provides references to clinicians for the management of rare DIIHA.PMID:37522435 | DOI:10.1177/10600280231189897 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 31, 2023 Category: Drugs & Pharmacology Authors: Linlin Tang Chuanhua Ding Hongying Li Xueheng Zhou Guoqiang Yin Source Type: research
A Real-World Disproportionality Analysis of Drug-Induced Immune Hemolytic Anemia in the FDA Adverse Event Reporting System
CONCLUSIONS: Our study identified the most common drugs that could induce DIIHA in adults and children, as well as the respective ROR and PRR value to discover new drug signals. This study provides references to clinicians for the management of rare DIIHA.PMID:37522435 | DOI:10.1177/10600280231189897 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 31, 2023 Category: Drugs & Pharmacology Authors: Linlin Tang Chuanhua Ding Hongying Li Xueheng Zhou Guoqiang Yin Source Type: research
A Real-World Disproportionality Analysis of Drug-Induced Immune Hemolytic Anemia in the FDA Adverse Event Reporting System
CONCLUSIONS: Our study identified the most common drugs that could induce DIIHA in adults and children, as well as the respective ROR and PRR value to discover new drug signals. This study provides references to clinicians for the management of rare DIIHA.PMID:37522435 | DOI:10.1177/10600280231189897 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 31, 2023 Category: Drugs & Pharmacology Authors: Linlin Tang Chuanhua Ding Hongying Li Xueheng Zhou Guoqiang Yin Source Type: research
A Real-World Disproportionality Analysis of Drug-Induced Immune Hemolytic Anemia in the FDA Adverse Event Reporting System
CONCLUSIONS: Our study identified the most common drugs that could induce DIIHA in adults and children, as well as the respective ROR and PRR value to discover new drug signals. This study provides references to clinicians for the management of rare DIIHA.PMID:37522435 | DOI:10.1177/10600280231189897 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 31, 2023 Category: Drugs & Pharmacology Authors: Linlin Tang Chuanhua Ding Hongying Li Xueheng Zhou Guoqiang Yin Source Type: research
A Real-World Disproportionality Analysis of Drug-Induced Immune Hemolytic Anemia in the FDA Adverse Event Reporting System
CONCLUSIONS: Our study identified the most common drugs that could induce DIIHA in adults and children, as well as the respective ROR and PRR value to discover new drug signals. This study provides references to clinicians for the management of rare DIIHA.PMID:37522435 | DOI:10.1177/10600280231189897 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 31, 2023 Category: Drugs & Pharmacology Authors: Linlin Tang Chuanhua Ding Hongying Li Xueheng Zhou Guoqiang Yin Source Type: research
Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma
IntroductionClassical Hodgkin lymphoma (cHL) is the most common pediatric lymphoma. Approximately 10% of patients develop refractory or recurrent disease. These patients are treated with intensive chemotherapy followed by consolidation with radiotherapy or high-dose chemotherapy and autologous stem cell reinfusion. Although this treatment is effective, it comes at the cost of severe long-term adverse events, such as reduced fertility and an increased risk of secondary cancers. Recently, promising results of inducing remission with the immune checkpoint inhibitor nivolumab (targeting PD-1) and the anti-CD30 antibody-drug co...
Source: Frontiers in Immunology - July 31, 2023 Category: Allergy & Immunology Source Type: research
Infections associated with bendamustine and anti-CD20 antibody in untreated follicular lymphoma: a real-world study
J Clin Exp Hematop. 2023 Jul 28. doi: 10.3960/jslrt.23015. Online ahead of print.NO ABSTRACTPMID:37518273 | DOI:10.3960/jslrt.23015 (Source: Journal of Clinical and Experimental Hematopathology : JCEH)
Source: Journal of Clinical and Experimental Hematopathology : JCEH - July 30, 2023 Category: Hematology Authors: Masuho Saburi Kazuki Okuhiro Natsumi Yoshida Takami Haruyama Yui Moroga Yuka Yanai Kazuhito Itani Kuniko Takano Shuhei Honda Keiji Ono Manami Iwanaga Hitohiro Sasaki Miyuki Abe Kazuhiro Kohno Toshiyuki Nakayama Eiichi Ohtsuka Masao Ogata Source Type: research
A case of classic Hodgkin lymphoma arising after remission of methotrexate-associated follicular lymphoma
J Clin Exp Hematop. 2023 Jul 28. doi: 10.3960/jslrt.23016. Online ahead of print.ABSTRACTHere we describe our experience with a rare case of methotrexate (MTX)-associated lymphoproliferative disorder (LPD) initially diagnosed as follicular lymphoma (FL) and then in relapse as classic Hodgkin lymphoma (CHL). A 66-year-old man was admitted to the hospital with fever and abdominal and lower back pain after a transient remission of MTX-associated FL (MTX-FL) following MTX withdrawal. Computed tomography (CT) showed para-aortic lymphadenopathy, which was compatible with one of the previous FL lesions. We considered a relapse of...
Source: Journal of Clinical and Experimental Hematopathology : JCEH - July 30, 2023 Category: Hematology Authors: Yayoi Ueda Takehiro Tanaka Shoji Asakura Tomofumi Yano Source Type: research
Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
J Clin Exp Hematop. 2023 Jul 28. doi: 10.3960/jslrt.23017. Online ahead of print.NO ABSTRACTPMID:37518271 | DOI:10.3960/jslrt.23017 (Source: Journal of Clinical and Experimental Hematopathology : JCEH)
Source: Journal of Clinical and Experimental Hematopathology : JCEH - July 30, 2023 Category: Hematology Authors: Masuho Saburi Masanori Sakata Yousuke Kodama Keiichi Uraisami Hiroyuki Takata Yasuhiko Miyazaki Junpei Wada Shogo Urabe Eiichi Ohtsuka Source Type: research
Infections associated with bendamustine and anti-CD20 antibody in untreated follicular lymphoma: a real-world study
J Clin Exp Hematop. 2023 Jul 28. doi: 10.3960/jslrt.23015. Online ahead of print.NO ABSTRACTPMID:37518273 | DOI:10.3960/jslrt.23015 (Source: Journal of Clinical and Experimental Hematopathology : JCEH)
Source: Journal of Clinical and Experimental Hematopathology : JCEH - July 30, 2023 Category: Hematology Authors: Masuho Saburi Kazuki Okuhiro Natsumi Yoshida Takami Haruyama Yui Moroga Yuka Yanai Kazuhito Itani Kuniko Takano Shuhei Honda Keiji Ono Manami Iwanaga Hitohiro Sasaki Miyuki Abe Kazuhiro Kohno Toshiyuki Nakayama Eiichi Ohtsuka Masao Ogata Source Type: research
A case of classic Hodgkin lymphoma arising after remission of methotrexate-associated follicular lymphoma
J Clin Exp Hematop. 2023 Jul 28. doi: 10.3960/jslrt.23016. Online ahead of print.ABSTRACTHere we describe our experience with a rare case of methotrexate (MTX)-associated lymphoproliferative disorder (LPD) initially diagnosed as follicular lymphoma (FL) and then in relapse as classic Hodgkin lymphoma (CHL). A 66-year-old man was admitted to the hospital with fever and abdominal and lower back pain after a transient remission of MTX-associated FL (MTX-FL) following MTX withdrawal. Computed tomography (CT) showed para-aortic lymphadenopathy, which was compatible with one of the previous FL lesions. We considered a relapse of...
Source: Journal of Clinical and Experimental Hematopathology : JCEH - July 30, 2023 Category: Hematology Authors: Yayoi Ueda Takehiro Tanaka Shoji Asakura Tomofumi Yano Source Type: research
